On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in ...
Alternative for treatment failure: parenteral therapy (home or hospital); sputum culture-based or adjusted therapy; consider referral to specialist Group III (suppurative CB) First-line oral ...
The researchers found that 80.7% of the patients in the standard-therapy group had favorable outcomes in the modified intention-to-treat analysis. (HealthDay News) — Three all-oral shortened regimens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback